xB3-002: Glioblastoma Study

"For the 002 program in glioblastoma, the Company plans to complete pre-clinical proof-of-concept (POC) (Q4 of 2018), initiate manufacturing (Q1 of 2019) and initiate toxicology studies (Q4 of 2019)."

From slide 17 of the recent June 2018 Corporate Presentation, it appears that biOasis will be working with Minerva Imaging to perform this pre-clinical proof-of-concept work. 

Target: Glioblastoma, one of the most aggressive cancers that originates within the brain, with 80% of diagnosed primary malignant brain tumors are malignant gliomas. Deadliest form of brain cancer due to high infiltration of surrounding brain tissues.

Treatment: Invasive surgical removal accompanied by subsequent radiation and chemotherapy.

Glioblastoma mouse model collaboration with Minerva Imaging

• Tissue distribution pattern

• Target engagement and PD biomarker

• Efficacy

From Minerva Imaging website: "Minerva Imaging is a scientifically driven CRO founded in 2011. Our focus is on the use of advanced oncology models and molecular imaging for translational cancer research and drug development."